NRx Pharmaceuticals
NRXP
NRx Pharmaceuticals (NRXP) news
Recent news
NRX Pharmaceuticals - reports cash and cash equivalents of $26.70 mln as of June 30, 2026
AInvest Wire · Aug 17, 2026Nrx Pharmaceuticals - FDA to review certification in shortest possible cycle after Aug 6, 2026 meeting
AInvest Wire · Aug 7, 2026NRX Pharmaceuticals - on July 21, NRX D selected by DARPA for negotiation of potential SPARC-TMS clinical trial award - SEC filing
AInvest Wire · Jul 22, 2026NRX Pharmaceuticals: Co does not believe that acquisition/non-acquisition of any individual clinic would be material to Hope's overall business model
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has expanded its network of interventional psychiatry clinics through the acquisition of Dura Medical, along with pending acquisitions of Neurospa TMS and Cohen & Associates. These acquisitions are expected to…
AInvest Wire · Jun 25, 2026NRX Pharmaceuticals - initiates arbitration with Kadima over failed closing conditions
AInvest Wire · Jun 25, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.